

MolMed enters into a strategic collaboration with GSK for development, manufacturing and technology transfer in gene therapy

Milan (Italy), 20 March 2015 – MolMed S.p.A. (MLM.MI) announces that it has entered into a strategic agreement with GlaxoSmithKline (GSK), under which MolMed will supply development, manufacturing and technology transfer services aimed at the clinical application of gene therapies based on viral vector cellular transduction.

As part of the agreement, MolMed will provide its expertise in process development and its manufacturing competencies and capacity for the production of viral vectors and cell transduction.

Under the terms of the agreement, MolMed would be eligible for a minimum of € 34 million in the form of upfront, milestones, services and supply, over the next five years. In particular, GSK will pay to MolMed during the next 12 months starting from the effective date of the agreement an amount related to the upfront and milestones equal to approximately €6 million.

Claudio Bordignon, Chairman and CEO of MolMed, commented: *"We are extremely pleased with this new agreement with GSK, which follows those signed in 2011 and 2013 and strengthens the collaboration between the two companies in the highly innovative field of gene therapies. This agreement acknowledges the substantial investment the company has made in its development labs and in additional production facilities, ultimately placing MolMed in a leadership position in the global industry"*.

This press release is written in compliance with public disclosure obligations established by CONSOB (Italian securities & exchange commission) resolution no. 11971 of 14 May 1999, as subsequently amended.

About MolMed

MolMed S.p.A. is a biotechnology company focused on research, development and clinical validation of novel anticancer therapies. MolMed's pipeline includes two antitumour therapeutics in clinical development: TK, a cell-based therapy enabling bone marrow transplants from partially compatible donors, in absence of post-transplant immune-suppression, in Phase III in high-risk acute leukaemia; NGR-hTNF, a novel vascular targeting agent, in Phase III in malignant pleural mesothelioma and in Phase II in six more indications: colorectal, lung (small-cell and non-small-cell), liver and ovarian cancer, and soft tissue sarcomas. MolMed also offers top-level expertise in cell and gene therapy to third parties to develop, conduct and validate projects from preclinical to Phase III trials, including scale-up and cGMP production of clinical-grade viral vectors, and manufacturing of patient-specific genetically engineered cells. MolMed is headquartered at the San Raffaele Biomedical Science Park in Milan, Italy. The Company's shares are listed on the main market (MTA) of the Milan Stock Exchange. (Ticker Reuters: MLMD.MI)

FROM GENES TO THERAPY

MOLMED S.p.A.

Via Olgettina, 58 - 20132 Milan, Italy | Phone +39 02 21277.1 - Fax +39 02 21277.325
info@molmed.com - www.molmed.com

Share capital € 11,019,314.98 fully paid - Office of Milan Company Registry number 1506630 - Tax identification number 11887610159



PRESS RELEASE

For further information:

Marina Del Bue

**General Manager Corporate Governance & Administration
Investor Relations Director *ad int.***

MolMed S.p.A.

phone: +39 02 21277.411

fax: +39 02 21277.325

e-mail: investor.relations@molmed.com

Press agent

Federico Ferrari

SEC Relazioni Pubbliche e Istituzionali srl

phone: +39 02 6249991 – mobile +39 347 6456873

e-mail: ferrari@secrp.it

DISCLAIMER

This press release may contain certain forward-looking statements. Although the Company believes its expectations are based on reasonable assumptions, these forward-looking statements are subject to numerous risks and uncertainties, including scientific, business, economic and financial factors, which could cause actual results to differ materially from those anticipated in the forward-looking statements. The company assumes no responsibility to update forward-looking statements or adapt them to future events or developments. This document does not constitute an offer or invitation to subscribe or purchase any securities of MolMed S.p.A.